Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
$54.65
+0.2%
$54.50
$37.28
$57.35
$4.50B-0.41.86 million shs15.31 million shs
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
$7.83
-5.2%
$7.91
$5.85
$24.17
$234.77M2.43398,593 shs522,182 shs
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
$13.81
-1.6%
$13.62
$5.04
$17.15
$407.14M1.01170,671 shs269,711 shs
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
$0.20
$0.20
$0.18
$1.94
$9.52M1.573.75 million shsN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$36.15
+2.5%
$52.20
$22.51
$60.08
$1.43B0.61406,491 shs545,018 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
0.00%0.00%0.00%0.00%+36.59%
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
+0.12%-9.53%-2.36%+15.20%-30.35%
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-3.44%-7.94%-1.68%+1.37%+168.26%
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
0.00%0.00%0.00%0.00%-87.95%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
-3.61%-39.73%-40.82%-31.21%+43.33%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
$54.65
+0.2%
$54.50
$37.28
$57.35
$4.50B-0.41.86 million shs15.31 million shs
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
$7.83
-5.2%
$7.91
$5.85
$24.17
$234.77M2.43398,593 shs522,182 shs
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
$13.81
-1.6%
$13.62
$5.04
$17.15
$407.14M1.01170,671 shs269,711 shs
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
$0.20
$0.20
$0.18
$1.94
$9.52M1.573.75 million shsN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$36.15
+2.5%
$52.20
$22.51
$60.08
$1.43B0.61406,491 shs545,018 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
0.00%0.00%0.00%0.00%+36.59%
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
+0.12%-9.53%-2.36%+15.20%-30.35%
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-3.44%-7.94%-1.68%+1.37%+168.26%
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
0.00%0.00%0.00%0.00%-87.95%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
-3.61%-39.73%-40.82%-31.21%+43.33%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
2.10
Hold$60.8011.25% Upside
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
2.67
Moderate Buy$25.44224.96% Upside
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
2.75
Moderate Buy$20.2946.89% Upside
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
1.00
SellN/AN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.43
Hold$38.807.33% Upside

Current Analyst Ratings Breakdown

Latest ENTA, PAHC, ARCT, AKRO, and EPIX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Lower Price TargetNeutral$62.00 ➝ $44.00
5/8/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
DowngradeBuy (B)Buy (B-)
4/21/2026
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
UpgradeSell (E+)Sell (D-)
4/20/2026
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
Reiterated RatingSell (D-)
4/15/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Initiated CoverageNeutral$62.00
4/15/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Initiated CoverageHold$62.00
3/26/2026
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
Initiated CoverageBuy$20.00
3/18/2026
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Initiated CoverageNeutralBuy$22.00
3/17/2026
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
UpgradeStrong-Buy
3/11/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
UpgradeHoldStrong-Buy
3/5/2026
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Lower Price TargetBuy$66.00 ➝ $21.00
(Data available from 5/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
N/AN/AN/AN/A$10.75 per shareN/A
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
$82.03M2.71N/AN/A$6.73 per share1.16
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
$65.32M6.14N/AN/A$3.03 per share4.56
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
N/AN/AN/AN/A$2.81 per shareN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$1.30B1.13$3.35 per share10.78$8.92 per share4.05
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
-$252.06M-$1.94N/AN/AN/AN/A-15.86%-14.78%N/A
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
-$65.78M-$2.81N/AN/AN/A-143.80%-36.55%-28.40%N/A
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-$81.89M-$2.59N/AN/AN/A-89.56%-68.72%-20.41%8/10/2026 (Confirmed)
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
-$28.54M-$0.56N/AN/AN/AN/A-21.71%-21.22%N/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$48.26M$2.3312.0310.950.546.35%37.14%8.57%6/30/2026 (Confirmed)

Latest ENTA, PAHC, ARCT, AKRO, and EPIX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/11/2026Q2 2026
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-$0.46-$0.45+$0.01-$0.45$17.03 million$17.16 million
5/7/2026Q1 2026
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
-$1.0320-$0.95+$0.0820-$0.95$6.30 million$2.06 million
5/6/2026Q3 2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.72$0.76+$0.04$0.59$367.02 million$383.54 million
3/3/2026Q4 2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
-$0.92-$1.03-$0.11-$1.0230$14.32 million$7.20 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
N/AN/AN/AN/AN/A
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
N/AN/AN/AN/AN/A
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
N/AN/AN/AN/AN/A
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
$1.69839.96%N/AN/A N/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.481.33%N/A20.60%N/A

Latest ENTA, PAHC, ARCT, AKRO, and EPIX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/5/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
quarterly$0.120.85%6/3/20266/3/20266/24/2026
1/1/2100
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
--$1.698/25/20258/19/20258/22/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
N/A
15.84
15.83
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
N/A
6.31
6.31
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
N/A
4.44
4.44
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
N/A
69.06
69.06
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1.97
3.17
1.26

Institutional Ownership

CompanyInstitutional Ownership
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
N/A
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
94.54%
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
94.99%
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
75.12%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
99.34%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
3082.32 million76.50 millionOptionable
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
18028.42 million23.36 millionOptionable
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
16029.02 million25.69 millionOptionable
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
5047.31 million39.98 millionOptionable
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2,47540.56 million20.22 millionOptionable

Recent News About These Companies

Phibro Animal Health Q3 Earnings Call Highlights

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Akero Therapeutics stock logo

Akero Therapeutics NASDAQ:AKRO

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Arcturus Therapeutics stock logo

Arcturus Therapeutics NASDAQ:ARCT

$7.83 -0.43 (-5.21%)
Closing price 04:00 PM Eastern
Extended Trading
$8.14 +0.31 (+3.95%)
As of 07:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Enanta Pharmaceuticals stock logo

Enanta Pharmaceuticals NASDAQ:ENTA

$13.81 -0.22 (-1.57%)
Closing price 04:00 PM Eastern
Extended Trading
$13.80 -0.01 (-0.04%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

ESSA Pharma stock logo

ESSA Pharma NASDAQ:EPIX

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$36.15 +0.89 (+2.52%)
Closing price 04:00 PM Eastern
Extended Trading
$36.72 +0.57 (+1.58%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.